GPT and metabolic dysfunction-associated steatotic liver disease: Novel pharmacotherapies for NAFLD are urgently needed.26 SGLT-2i is a potential option: in the E-LIFT (effects of empagliflozin on liver fat content in patients with type 2 diabetes) trial empagliflozin significantly reduced liver fat and improved liver enzymes.7 Pooled data in the EMPA-REG outcome study (empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus patients) demonstrated that empagliflozin reduced ALT independent of body weight.25 However, efficacy and safety may be limited in those with renal impairment.